MB-61MEDULLOBLASTOMA - WHY IS THE 5-YEAR OVERALL PROGRESSION-FREE SURVIVAL NOT IMPROVING?
نویسندگان
چکیده
منابع مشابه
Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma.
BACKGROUND Thalidomide maintenance therapy after stem cell transplantation resulted in increased progression-free survival and overall survival in a few trials, but its role in non-transplant eligible patients with multiple myeloma remains unclear. This study assessed the impact of thalidomide-interferon in comparison to interferon maintenance therapy in elderly patients with multiple myeloma. ...
متن کاملModeling the relationship between progression-free survival and overall survival: the phase II/III trial.
The standard phase II trial design has changed dramatically over the past decade. Randomized phase II studies have essentially become the standard phase II design in oncology for a variety of reasons. The use of these designs is motivated by concerns about the use of historical data to determine if a new agent or regimen shows promise of activity. However, randomized phase II designs come with ...
متن کاملMeta-analysis for the association between overall survival and progression-free survival in gastrointestinal stromal tumor.
PURPOSE Gastrointestinal stromal tumor (GIST) is a relatively rare tumor that is treated with targeted therapies in advanced stages. Randomized clinical trials (RCT) often require long follow-up and large sample sizes to evaluate overall survival (OS), the gold-standard measure of treatment efficacy. However, changes in therapy following disease progression may complicate survival assessments. ...
متن کاملAdding Erlotinib to Chemoradiation Improves Overall Survival but not Progression-Free Survival in Stage III Non-Small-Cell Lung Cancer
PURPOSE To test, in a single-arm, prospective, phase 2 trial, whether adding the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib to concurrent chemoradiotherapy for previously untreated, locally advanced, inoperable non-small cell lung cancer would improve survival and disease control without increasing toxicity. METHODS AND MATERIALS Forty-eight patients with prev...
متن کاملTherapeutic effect of apatinib on overall survival is mediated by prolonged progression-free survival in advanced gastric cancer patients
Apatinib is reported to significantly improve the overall survival (OS) of patients with advanced gastric cancer who have previously failed second-line chemotherapy. However, it is not well understood whether apatinib acts by improving progression or by prolonging post-progression survival. Here, based on phase III clinical trial data, the mediating effect of apatinib on patient overall surviva...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neuro-Oncology
سال: 2016
ISSN: 1522-8517,1523-5866
DOI: 10.1093/neuonc/now076.57